Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RA-CX3CR1
- Development stage
- Unknown
- Modality
- Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intrathecal
01
Overview
RA-CX3CR1 (also known as TP501) is a rabbit polyclonal neutralizing antibody directed against the C-X3-C motif chemokine receptor 1 (CX3CR1). Developed by Torrey Pines Biolabs, it is primarily used as a research-use-only reagent to study the role of the fractalkine (CX3CL1)/CX3CR1 signaling pathway in various physiological and pathological processes, such as neuropathic pain, diabetic neuropathy, and inflammatory responses. In animal models, intrathecal or systemic administration of RA-CX3CR1 has been shown to attenuate mechanical allodynia and microglia activation, highlighting its utility in preclinical pain and inflammation research.
- Other names
- rabbit anti-CX3CR1 antibodyrabbit anti-rat CX3CR1 pAbrabbit anti-rat CX3CR1 polyclonal antibody
02
Targets
CX3CR1 (C-X3-C motif chemokine receptor 1)
Beyond the preview
Go deeper on RA-CX3CR1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RA-CX3CR1.